Re: Childhood Lipid Screening: Evidence and Conflicts
McCrindle et al titled their response to our commentary, "Bringing Evidence to the Debate." However, they primarily reiterated the rationale already in the guidelines, rather than bringing new evidence to address our concerns.
One concern was that the guideline did not address the cost-efficacy of its recommendations. McCrindle et al cited studies of the cost-efficacy of screening for the rare (1 in 500) genetic condition familial hypercholesterolemia (FH) . However, such a narrowly focused screening program was not recommended in the guideline. The $8700 per year gained that they quote is irrelevant because it refers to a program to screen family members of known FH cases, 1 not to the population-wide screening program they recommend, which would be far less cost-effective. 3. Trials of whether treating the much larger number of children with high lipid levels as recommended by the proposed guidelines reduces future coronary events have not been done and are unlikely ever to be feasible.
Our areas of disagreement relate both to the aggressive nature of the National Heart, Lung, and Blood Institute guidelines and to the process by which they were produced.
1. We disagree that it is acceptable to make screening recommendations without estimating the health benefits, harms, and costs that might result. Because such estimates are essential for informed decision-making, we disagree that the "guidelines provide clinicians with the necessary evidence … to make their own informed judgment as to the utility and role for these recommendations."
2. In the absence of randomized trial evidence of clinical event benefits, we disagree with making a "strong recommendation," requiring a "compelling rationale for an alternative approach" (quoted from Tables 1-3 Conflicts of interest among authors of guidelines were discussed in a recent report 3 from the Institute of Medicine (IOM). With the exception of disclosing conflicts, none of the panel' s recommendations were followed (Table) .
The panel members, however wellmeaning, are only human, and it is unreasonable to believe that the large body of research on conflicts of interest that led to the IOM recommendations does not apply to them. A flawed process led to overly aggressive guidelines in which the strength of the evidence was misrepresented and key evidence needed to evaluate the guidelines was lacking. We can and should do better. Let' s start by following this key IOM recommendation: scientists with extensive conflicts of interest should not be permitted to have leadership or voting roles on guideline panels. Universal lipid screening is the most discussed issue in the guidelines. It was also widely debated within the subgroup reviewing the evidence, risks, and benefits, as well as by the entire panel. The consensus recommendation is to assess all children between 9 and 11 years of age with a nonfasting non-high-density lipoprotein cholesterol (non-HDL-C 5 total cholesterol -HDL-C) level. The primary purpose of screening is to identify the ∼1 in 500 children who are heterozygous for familial hypercholesterolemia (FH), realizing that other forms of important dyslipidemia would be identified as well. Children with FH have elevated total and lowdensity lipoprotein cholesterol levels from birth and are at risk for early cardiovascular disease; 5% of individuals with this condition will have a coronary artery event before 30 years of age. Previous guidelines have relied on family history to initiate
screening, but the evidence shows this approach to be insufficient. 3, 4 The panel concluded that universal screening was necessary to detect this important, common family condition. The nonfasting non-HDL-C level is an accurate screen for dyslipidemia, and elimination of the need to be fasting should make testing easier. Age 9 to 11 years was selected because most children entering fifth or sixth grade are required to have a health maintenance examination and because low-density lipoprotein cholesterol levels fall with puberty before rising to prepuberty levels. An additional benefit to screening of children is the identification of parents who are unaware that they have FH. Knowing a child' s cholesterol level can initiate family screening and a targeted lifestyle intervention.
Providers of children' s health care are familiar with screening to identify disease states that do not present on physical examination. As the medical home for children and families, we use behavioral screening to identify conditions such as maternal depression, developmental delay, and autism. We assess for disease states and behaviors throughout childhood, although their sequelae may not be manifest until adulthood. An example is screening for tobacco use. Pediatric care providers are therefore well positioned to identify children with dyslipidemia who need early intervention to prevent development of premature cardiovascular disease.
The guidelines have only been available for 1 year, and it will take more time to become familiar and comfortable with the recommendations. Following the risk factor algorithms makes it clear that the guidelines only rarely recommend specialist referral. Rather, the approach is risk identification and management by the primary care practitioner. Just as those of us who care for children have
